To include your compound in the COVID-19 Resource Center, submit it here.

USL311: Phase I/II started

Upsher-Smith began an open-label, dose-escalation, international Phase I/II trial to evaluate once-weekly

Read the full 120 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE